Introduction
It’s widely known that the results in at least half of all life-published science studies cannot be reproduced when researchers try to verify results. What’s less known is what happens when potential therapeutics move from the lab to companies looking to develop new drugs and treatments.
Christine Brideau is well-acquainted with this verification gap from her work at the fulcrum of turning basic research into products working at Deerfield Deerfield Discovery & Development, LLC (3DC) and previously at WuXi and Merck. During her recent Tuesday Talk, Christine described recent studies on reproducibility from Bayer and Amgen, shared her own experience and insights, and offered suggestions for narrowing the verification gap.
